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To examine how the presentation of a decision can influence choices about genetic 
testing for inherited cancer predispositions. Specifically, how the number of options and 
the addition of a personalized recommendation might influence outcomes such as the 
likelihood of undergoing genetic testing, the genetic test chosen, and whether a person’s 
test choice matches their personal preferences. 
Methods: 
An online hypothetical vignette study was completed by 454 healthy volunteers.  Each 
participant was randomized to receive one of two survey versions which differed in the 
manner of presenting testing options and how these options were integrated with a 
provider recommendation. Regression analyses were performed to determine the 
relationships between the presentation of choice and participant decisions. Wilcoxon 
rank-sign tests were used to determine the impact of a provider recommendation on final 
genetic testing choices.  
Results:  
Participants were more likely to choose to undergo genetic testing when presented with 
three options instead of two (OR: 2.00 p=0.014).  This effect was no longer observed 
when individuals who had decided not to undergo testing were presented with a third 
option (OR: 0.90 p=0.775).   The addition of a provider recommendation did not 
significantly change the overall distribution of options chosen (p=0.746). However, after 
a recommendation, participants were more likely to choose the test that best matched 




Participants are more likely to undergo genetic testing when presented with more options.  
They are also more likely to select an option in line with a personal preference if 
presented with a recommendation based on this preference. 
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PART 1: INTRODUCTION 
ORGANIZATION OF THESIS 
Part 1: Contains an overview of the organization of the thesis, an executive summary, the 
thesis objective and aims, a comprehensive literature review, and a detailed review of the 
methods 
Part 2: Is a manuscript that focuses on the three thesis aims. Analytic methods and results 
for each specific aim are not addressed in this thesis, as the option to write a manuscript 
was selected. Additional results will be published in future manuscripts.  
EXECUTIVE SUMMARY 
Next-generation sequencing technologies have enabled the proliferation of panel 
genetic tests for inherited cancer predispositions. The growing number of testing options 
has made it more challenging for healthcare providers to decide which tests to offer and 
how to present them to patients because there may be multiple medically appropriate 
options. How providers present decisions is important because it can influence the 
choices that patients make and their subsequent medical care (Thaler & Sunstein, 2009).  
The purpose of this study is to examine how the presentation of genetic testing might 
influence whether people decide to undergo genetic testing and the specific test they may 
choose.  Understanding how the presentation of genetic testing influences decisions is the 
first step toward helping providers build an evidence-based practice for presenting 
decisions in a way that maximizes client understanding and engagement in the decision-
making process. This study seeks to address the three aims outlined below.   
The first aim is to determine the impact of adding a third option on the decision to 
have genetic testing or not.  Research in other fields has shown that adding additional 
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options can influence the selection of preexisting options (Tversky & Kahneman, 1974).  
This is believed to occur because adding an additional point of comparison can change 
how people evaluate options.  The specific way in which adding another option 
influences choice depends on the relative attractiveness of the options.  At this time, it is 
unknown how people view the relative attractiveness of different genetic testing options 
and how they weigh tradeoffs in the decision-making process. This study seeks to 
determine if individuals are more or less likely to undergo genetic testing when presented 
with an additional genetic panel test.  
The second aim is to examine the impact of a provider recommendation on 
genetic testing choice.  Previous studies have indicated that many individuals would like 
a recommendation about genetic testing (Geller & Bernhardt, 1998; Vadaparampil, 
McIntyre, & Quinn, 2010). This study uses survey logic to give each participant who 
chose to undergo genetic testing a recommendation for one of the two genetic tests and 
the opportunity to change their previous decision.  Each recommendation is based on the 
participants answer to a question about whether they would prefer to learn only clinically 
actionable genetic information or all possible genetic information.   The impact of the 
recommendation is determined by examining whether the distribution of tests chosen 
differs before and after the recommendation.  Additionally, this study investigates 
whether the test selected is more likely to match the individual’s information preference 
after the targeted recommendation.  
The third aim is to determine if the overall method of offering testing, which 
integrates the complete process of presenting genetic testing options and a provider 
recommendation, influences outcomes.  These outcomes include the overall distribution 
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of which genetic testing options are chosen, and the likelihood of undergoing testing.  
Furthermore, because adding another option increases the amount of information that 
decision makers need to process and therefore the complexity of the decision, this study 
examines if the overall method of genetic testing relates to patient reports of decisional 
conflict. 
OBJECTIVE AND SPECIFIC AIMS 
Objective: To examine the impact of the number of options and a provider 
recommendation on a hypothetical decision about genetic testing for hereditary cancer 
predisposition.  
Aim 1: To examine the impact of adding a third genetic testing option on the likelihood 
of having genetic testing. 
Question 1.1:  What is the impact of adding a third option on the decision to have genetic 
testing or not?  
Sub-question 1.1: Would the outcome change if non-testers who were presented 
with two options are offered a third option after they have made their initial 
genetic testing choice? 
Aim 2: To examine the impact of a provider recommendation on genetic testing choice. 
Question 2.1: Does genetic test choice differ after a personalized recommendation?  
Question 2.2: Does a provider recommendation influence the likelihood that the final test 
choice matches the participant’s information preference and the corresponding provider 
recommendation among testers? 
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Question 2.3: Does the test presentation method influence the likelihood that the final test 
choice matches the participant’s information preference and the corresponding provider 
recommendation among testers?  
Aim 3: To examine the relationship between the overall method of testing presentation, 
the choices made and decisional conflict. 
Question 3.1:  Does the genetic testing presentation method impact the final genetic 
testing option chosen? 
Question 3.2:  Does the genetic testing presentation method impact the final likelihood of 
undergoing testing? 
Question 3.3: Does test offering method relate to decisional conflict and is this 
relationship mediated by information preference/test choice concordance?  
LITERATURE REVIEW 
Conceptual Framework 
 The objective of this study is to investigate if altering the presentation of genetic 
testing decisions can influence the choices made. Specifically, this study seeks to 
investigate if manipulating the number of testing options offered and adding a provider 
recommendation can influence patient decisions within the context of hypothetical 
hereditary cancer predisposition testing.  These are characteristics of a healthcare 
encounter that a provider is likely to vary -- either purposively or not.  By better 
understanding how the presentation of a choice may influence the process of patient 
decision-making we can more effectively help patients to make decisions more closely 
aligned with their preferences. 
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The conceptual model underlying this investigation is based on a decision-making 
model that proposes three main categories of factors that influence choice (Figure 1).  
These factors are divided into attributes of the problem, person and social context of the 
decision (Payne, 1993).  Specifically, this study focuses on examining the impact of 
problem-related attributes on genetic test choice. Problem-related attributes are intrinsic 
aspects of the structure and presentation of a choice and can be divided into task and 
context components. Task effects describe structural characteristics of the decision 
problem, for example, method of response, number of outcomes, number of alternatives, 
time pressures, and information display (Payne, 1993). Context components include 
factors associated with the value of attributes in a specific decision context, including the 
similarity and overall attractiveness of alternatives. The second category of factors, 
person-variables, are attributes of the decision maker, such as the decision maker’s 
cognitive ability and prior knowledge (Payne, 1993). Some person-variables are also 
measured as a part of this study.  
While the social context within which a decision is made also influences decision 
making, this is not examined in this investigation. 
Introduction to Hereditary Cancer Syndromes 
Cancer is the second leading cause of death in the United States, surpassed only by 
Heart Disease (Hoyert & Xu, 2011).  In fact, 1 in 2 men and 1 in 3 women in the United 
States will develop cancer at some point in their lifetimes (American Cancer Society, 
2013). Cancer is composed of abnormal cells that develop different biochemical 
properties that confer enhanced abilities to proliferate and survive. They acquire these 
biochemical attributes through a series of genetic and/or epigenetic changes that occur in 
6 
 
a way that gives that cell a competitive advantage over neighboring cells (Schneider, 
2012).  Some individuals are born with a genetic mutation that places them at an 
increased lifetime risk to develop specific types of cancer, often at younger ages than 
people in the general population.  These individuals are said to have a hereditary cancer 
syndrome, and it is believed that about 5-10% of all cancers are inherited via this 
mechanism (Garber & Offit, 2005). There are at least 45 identified syndromes with clear 
genetic causes that confer an increased lifetime risk of developing cancer (Riley et al., 
2012).  These syndromes can differ on many dimensions including the types of cancer, 
the magnitude of the risks, the inheritance pattern, and whether individuals have other 
physical symptoms.  Some hereditary cancer syndromes have been well described and 
studied for many years, while others are poorly understood. 
Many types of cancer are associated with hereditary syndromes including breast, 
colon, ovarian, pancreatic, and kidney cancers (Schneider, 2012). Two of the most 
common hereditary cancer syndromes are Hereditary Breast and Ovarian Cancer 
Syndrome (HBOC) and Lynch Syndrome also known as Hereditary Non-Polyposis 
Colorectal Cancer syndrome. HBOC is caused by a deleterious mutation in either the 
BRCA1 or BRCA2 gene (Garber & Offit, 2005). This syndrome is associated with high 
lifetime risks of developing certain cancers which exceed general population risk 
including up to an 80% lifetime chance to develop female breast cancer, 40% chance to 
develop ovarian cancer, and elevated risks for prostate and pancreatic cancers (Petrucelli, 
Daly & Feldman, 2013).  Approximately 1 in 800 women in the general population and 1 
in 40 women of Ashkenazi Jewish ancestry have this syndrome (Schneider, 2012). In 
contrast, Lynch syndrome can be caused by a mutation in one of six different genes and 
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increases the chance of developing colorectal, endometrial, ovarian, small bowel, 
hepatobiliary, and urinary tract cancers. Most hereditary cancer syndromes including 
HBOC and Lynch Syndrome are inherited in an autosomal dominant manner; however, 
there are several syndromes which are inherited in an autosomal recessive manner, x-
linked recessive manner or via parental imprinting disorders (Schneider, 2012).  
Genetic Testing for Hereditary Cancer Syndromes 
Genetic testing on a blood or saliva sample can be used to identify individuals 
with hereditary cancer syndromes and inform their cancer risk assessments. Individuals 
identified at elevated risks for cancer by genetic testing may use these results to guide 
medical management decisions about cancer treatment, screening and/or prevention with 
the objective of reducing cancer morbidity and mortality. For example, women identified 
as having HBOC may decide to have increased breast surveillance or have prophylactic 
surgeries such as a bilateral mastectomy or salpingo-oophorectomy due to their high risk 
of breast and ovarian cancers. Genetic test results can also be useful for informing cancer 
risks and guiding genetic testing in relatives. However, not all information from genetic 
testing is considered clinically actionable. For example, it is possible to learn about risks 
for cancers that cannot be screened for or prevented.  Genetic tests can also yield results 
that are uninformative or unclear.   For instance, a negative test result in the absence of a 
known mutation in a family does not indicate a decreased risk of cancer. Additionally, 
some genetic changes are not understood well enough to be classified as disease causing 
or not.  These genetic changes are called variants of uncertain significance. 
Typically, a person would come to clinical attention as a candidate for hereditary 
cancer testing based on a notable family or personal history of cancer or if a mutation is 
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identified in a relative. Elements suggestive of a hereditary cancer syndrome in the family 
include a family history with many cases of an uncommon cancer, cancer occurring at 
younger ages, multiple family members with a certain constellation of cancers, or a 
person with multiple primary cancers (American Cancer Society, 2013). In cases where 
the client sees a genetic counselor, the counselor would perform a risk assessment based 
on the client’s personal medical information and family history of cancer (Riley et al., 
2012).  This risk assessment would serve to determine whether the client could be 
considered to have an average, modest, or increased cancer risk using a subjective 
assessment and sometimes empirical cancer risk models (Riley et al., 2012). The 
counselor would then determine whether the client is a candidate for genetic testing, and 
if so decide which genetic tests to offer and how to offer them. Clients who are offered 
testing then need to make a decision about whether or not to have genetic testing and 
potentially which test they would prefer to have. 
These decisions have become more complex over time as new technologies such 
as next-generation sequencing have enabled the sequencing of multiple genes 
simultaneously (Hall, Forman, & Pilarski, 2014). Consequently, it is possible to test 
multiple genes on a single panel test and as a result many companies have begun to offer 
a variety of panel tests that have opened up new approaches to genetic testing for cancer 
risk assessment. At this time there are 4 general approaches to cancer genetic testing 
including the following: 
1. Syndrome specific test (e.g. testing for HBOC) 
2. Cancer-specific high penetrance gene panel (e.g. genes for several syndromes that 
cause a high-risk for breast cancer) 
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3. Cancer-specific gene panel with high and moderate penetrance genes (e.g. many 
genes that have some association with increased breast cancer risk) 
4. “Comprehensive” cancer panels that include genes associated with multiple 
cancers or hereditary cancer syndromes ( e.g. genes associated with HBOC, 
Lynch Syndrome and other cancer syndromes) (Hall et al., 2014). 
Each of these approaches has distinct clinically relevant advantages and 
disadvantages which constitute trade-offs in choosing one method over another.  For 
example, testing a larger number of genes at a time may be more cost-effective, and may 
improve detection of cancer susceptibility mutations.  However, this approach can also 
lead to an increased likelihood of finding mutations in genes without evidence-based 
management strategies, receiving genetic variants of uncertain significance, and have a 
longer testing turn-around time (Hall et al., 2014). Given these challenges, National 
Comprehensive Cancer Network (NCCN) recommends that panels only be offered in the 
context of a consultation with a cancer genetics professional (NCCN, 2014).  
The Decision Making Process and Outcomes 
Because of the complexity of the tradeoffs, NCCN recommends that the benefits, 
limitations and management recommendations be reviewed by the provider and discussed 
with patients prior to ordering a multi-gene panel (NCCN, 2014). The National Society of 
Genetic Counselors (NSGC) recommends that  informed consent for genetic testing 
should include a discussion of the precise gene(s) being tested, the possible outcomes of 
testing, medical management issues specific to the test results, a review of the possible 
benefits, risks and limitations, and alternatives to genetic testing (Riley et al., 2012).  As 
the number of genes being testing increases, informed consent using this model is not 
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feasible, as cancer panels may include only a few genes or as many as 49 different genes 
(Hall et al., 2014). 
There are multiple approaches to studying medical decision-making. An 
investigator can decide to measure different aspects of the process such as the elements 
surrounding the task of decision making (e.g. role preference), the decision making 
process (e.g. deliberation), the decision itself, or the patient’s outcome post decision 
making (Scholl et al., 2011).  Additionally, a distinction can be drawn between 
observational measures of the competence of the parties involved in the decision and 
measures of the perception of the patient or clinician (Scholl et al., 2011). However, there 
is debate as to what constitutes a “good” decision and how the aforementioned attributes 
integrate into this assessment (Elwyn & Miron-Shatz, 2010).  
One study was conducted to elucidate the decision making process for decisions 
about predictive genetic testing used a simulated decision task.  The 20 participants in 
this study ranged in age from 18-34 years old, had no family history of a known genetic 
condition with available predictive testing, and had not considered the issue of genetic 
testing prior to participating in the study.  These individuals were given a hypothetical 
scenario about a genetic form of bone cancer that was found in their uncle, and they were 
asked to decide whether or not they would want to approach their general practitioner for 
genetic testing. The decision making process was examined by tracking what information 
participants viewed through an online program detailing testing information, and by 
examining their verbal explanations of their thought processes as they were making the 
decision.  Several distinct processes of decision making were identified including: the 
extent of consideration of alternatives, and the extent of evaluation of the information and 
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the perceived consequences of the available options. In this study, the most common 
features that participants viewed during the decision making process were information 
about genetic test attributes, disease characteristics and treatment attributes.  
Furthermore, the main factors that participants said they considered in their decision 
making process were disease treatment, concerns for family members, and reliability of 
the test, although other factors were also important for some individuals (Henderson, 
Maguire, Gray, & Morrison, 2006). 
The testing option chosen is important because the test results, or lack of test 
results, may have downstream medical and psychosocial consequences for the patient 
post-decision. For example, one study of 465 women who underwent BRCA1/2 testing 
found that mutation carriers were significantly more likely to undergo risk-reducing 
mastectomy, and/or risk-reducing oophorectomy than women who received other test 
results.  The researchers in this study found that more than 80% of carriers had undergone 
at least one of these risk-reducing surgeries indicating that testing likely has an indirect 
effect on cancer outcomes (Schwartz et al., 2012).  Increased screening behaviors have 
also been observed in carriers of these mutations (Heshka, Palleschi, Howley, Wilson, & 
Wells, 2008).  In thinking about psychosocial outcomes, one meta- analytic review of 
post-testing emotional distress in BRCA1/2 mutation carriers found that carriers 
experienced increased distress after receiving their results, however, the distress levels 
returned to pre-testing levels over time (Hamilton, Lobel, & Moyer, 2009).  This study 
also found that distress among non-carriers and those with inconclusive results decreased 




Advancements in decision-making science have occurred in multiple disciplines 
outside of the medical context including the fields of marketing, economics, and 
psychology. There are two fundamental paradigms for thinking about decision making 
evident in the literature. The first of these approaches is called the normative approach 
which assumes a rational decision maker with a well-defined preference (Mather, 
Verstraten, & Anstis, 1998). Essentially, this approach assumes that people use the 
information available to make the decision that is best for them and that the decision 
would remain consistent every time. The alternative paradigm is called the descriptive 
approach to decision making and involves examining decisions in practice.  Studies 
utilizing the descriptive approach to decision making have found  that peoples’ decisions 
deviate from the rational choice in predictable ways across many scenarios (Mather et al., 
1998).  This has relevance for providers who facilitate patient decisions because the way 
they frame and present choices can influence the decision made and its consequences.  
(Thaler & Sunstein, 2009). 
Presentation of Options 
One finding with relevance to scenarios in which patients are forced to choose from 
multiple medically appropriate options  is that the number of options presented influences 
the choice made (Tversky & Kahneman, 1974). In the theory of rational choice, it is 
implied that a preference between options cannot be altered by the addition of new 
alternatives.  However, there is evidence to suggest that people’s preference between two 
options can depend on the presence or absence of a third alternative (Simonson, 1989).  
This is thought to occur because the relative attractiveness of options can change as 
people evaluate them.  For example, when there are multiple attractive options, each of 
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which has advantages and disadvantages, people may delay making a decision, seek to 
maintain the status quo, or seek additional information.  In contrast, adding an additional 
option which appears less attractive can enhance the attractiveness of the comparison 
option and increase the likelihood that it is chosen (Mather et al., 1998).  
Furthermore, people may evaluate options differently when they are presented 
simultaneously than when they are presented separately from each other.  Changing the 
evaluation of options from a simultaneous to a separate evaluation can lead to a reversal 
of preferences. For example, in one study participants were asked to evaluate the 
appropriateness of a settlement from the sale of a lot owned by two neighbors.  Many 
participants preferred different options when asked to pick the better of the two 
settlements than when they were presented with each settlement separately and asked to 
indicate the acceptability of each on a rating scale. For example, 75% of participants 
judged option A as preferable to option B when evaluating both options simultaneously, 
and 71% rated option B as better than A when asked to rank each one separately 
(Bazerman, Loewenstein, & White, 2013).  It is hypothesized that some option attributes 
are easier to evaluate than others and difficult-to-evaluate attributes have a greater impact 
on joint evaluation than on simultaneous evaluation than easy-to-evaluate attributes 
(Hsee, Loewenstein, Blount, & Bazerman, 1999).   
Giving these findings, it is possible that offering additional genetic testing 
options, and altering the way these options are presented may influence whether an 
individual undergoes genetic testing and which test is chosen. However, there has been 
no work to examine how offering multiple genetic tests for one category of disease, such 
as hereditary cancer can influence these outcomes. Additionally, it is unclear how people 
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view the relative attractiveness of genetic panel tests that have tradeoffs correlated with 
the number of genes tested.  For example, testing more genes simultaneously has a 
greater cost effectiveness and higher likelihood of identifying an underlying genetic 
predisposition for cancer but there is also a higher likelihood of receiving a result that is 
uncertain or has unclear clinical utility (Hall et al., 2014). It is also unclear if the same 
attributes that may drive the choice of one test over another are the attributes most likely 
to influence medical and psychological outcomes.  
Provider Recommendations in Genetic Services 
 Historically, there has been a paradigm of non-directiveness in genetic services 
which is different from other medical fields which operated under a model of provider 
dictated medical care (Elwyn et al., 2001). Under the philosophy of non-directiveness, 
geneticists and genetic counselors should help clients arrive at decisions based on the 
client’s values and beliefs and not the opinion of the clinician (Elwyn, Gray, & Clarke, 
2000).  Non-directiveness is in part a reaction to the practice of eugenics and is one way 
that the field of genetics distinguishes itself from eugenic practices (Elwyn et al., 2000). 
However, genetics and some other medical fields have been moving away from non-
directiveness toward a shared decision-making process between patient and provider 
(Elwyn et al., 2001). As a part of this process, it may be appropriate for providers to give 
recommendations about genetic testing for inherited cancer predispositions. 
Furthermore, some studies have shown that many patients would prefer a 
recommendation about genetic testing.  One qualitative study about breast cancer 
susceptibility testing found that some women prefer to have a recommendation and that 
they differed in whether they preferred to be directed toward a single recommended 
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course of action, or whether they still wanted to hear all of the options available before 
making a decision (Geller, Strauss, Bernhardt, & Holtzman, 1997).  A survey of 426 
women considered at risk for breast cancer, reported that 82% of participants would want 
providers to make a recommendation about breast cancer susceptibility testing(Geller & 
Bernhardt, 1998).  Another group conducted qualitative interviews of Hispanic women at 
risk for HBOC and found that different sub-ethnicities differed in how they preferred 
their provider to make a genetic testing recommendation.  For example, groups of 
Mexican, Cuban and Puerto Rican women differed in whether they would rather have 
their provider urge them to get a genetic test, ask them to consider testing, or framed their 
recommendation in terms of what they recommend similar women to do (Vadaparampil 
et al., 2010). 
Patients may not only prefer a provider recommendation, but these 
recommendations can also be an important factor when patients make testing decisions.  
For example, in a study of 446 individuals with a known familial HNPCC mutation, 47% 
of the 299 individuals who underwent testing indicated that a physician’s 
recommendation was important in their decision (Aktan-Collan et al., 2000). 
Additionally, participants in a population-based study by Bosompra et al., (2000) 
indicated that participants were more likely to undergo testing with a provider 
recommendation.  
These investigations only account for recommendations of whether or not to 
undergo genetic testing, they do not examine the influence of provider recommendations 
in the context of more complex decisions related to which test is chosen.  
Hypothetical Vignettes in Genetics Research  
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 There have been numerous studies of patient-related factors that are predictors of 
testing uptake, mostly in the context of HBOC and Lynch Syndrome in both high risk and 
general populations.  In all of these studies, the decision was either a true or hypothetical 
binary decision of whether or not to undergo testing.  A meta-analysis of 40 studies of 
genetic testing uptake found that overall, hypothetical uptake was slightly higher (66%) 
than real uptake (59%).  
Hypothetical vignettes are commonly used for studying genetic testing decisions. 
This methodology has many advantages including cost-effectiveness, speed, and the 
ability to convey scenarios in a standardized way (Persky, Kaphingst, Condit, & 
McBride, 2007).  However, on a study by study basis, there is often a disparity between 
predicted and actual genetic testing rates (Persky et al., 2007).   Based on a review of 38 
articles that used a hypothetical vignette methodology, the authors identified a number of 
vignette elements related to reliably predicting genetic test uptake accuracy, including 
strategies to increase the realism of a scenario. Some of these strategies included 
mentioning a test administrator and making the test seem more temporally imminent.  
Additionally, they found that the presence or absence of a heredity description 
significantly influenced interest in testing.  Finally, they found that the number of words, 
sentences, and multisyllabic words were not associated with estimates of  testing uptake 
indicating that they neither improve the accuracy of uptake estimates or undermine the 
ability to engage with scenarios (Persky et al., 2007). 
METHODS 
Study Sample 
Study Population and Randomization 
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Potential study participants were recruited through their involvement in the 
healthy volunteers database at the National Institutes of Health.  This database contains 
individuals who are willing to be contacted about opportunities to participate as healthy 
volunteers in biomedical research studies through the NIH intramural research program.  
There were three specifications given to the healthy volunteers office for generating the 
list from the database.  These were that the list should contain approximately 3,000 
participants, participants must have text input in the email address field in their database 
entry, and should reflect a census representative distribution of ages as closely as possible 
which would be 1710 people in the 18-44 years old group, 870 people in the 45-64 years 
old group, and 420 in the 65 and over group. These three age strata were determined 
based on pre-existing classification of age in the database.  
The researchers received three lists from the office of healthy volunteers, one for 
each age strata with 3,083 people on the 18-44 list, 943 on the 45-64 list and 325 on the 
65+ list for a combined total of 4,351 potential participants. Participants who had text in 
the email field that was not an email address (e.g. “NO EMAIL”) and duplicate emails 
were removed from the list.   
The researchers then selected some participants from the list provided by the healthy 
volunteers office to create a census representative age distribution from each age group to 
create the desired list of approximately 3,000 participants.  This involved including all 
people in the 65+ age strata, because the number of people in this age group was low and 
a subset of people chosen using a random number generator from the other two age 
groups. Participants on this list were then assigned to either group 1 or group 2 using 
random number generation. 
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A sample size of 400, anticipating a 25% response rate based on previous 
literature on unsolicited online surveys, was determined to be sufficient to address the 
study questions. As it was unclear how many emails from the dataset would be viable and 
what the response rate would be, the investigator decided to invite a subset of people 
assigned each group to take the survey with the option to invite more people as needed to 
achieve the sample size target. For this subset, older age groups were oversampled in 
anticipation of a higher response rate in younger participants due to differences in 
internet usage patterns.  This subset was selected to contain 40% of people in 18-44 age 
group from the list of 3,000, 60% in the 45-64 age group, and all participants in the over 
65 age group which created a list of 1573 total invitees for both groups combined. An 
additional 7 individuals were randomized to receive an invitation to take either one of the 
surveys after contacting the researcher requesting participation. The demographics of this 
sample are reflected in Table 1.  
Survey Distribution 
 The lists of participant emails from each experimental group were uploaded into 
Qualtrics as panels.  An email message was then distributed to each panel. Consequently, 
each potential participant received an email with a message inviting him/her to participate 
in the study and a personalized link to the survey that enabled one-time completion of the 
survey and enabled the participant to return to a partially completed survey (Appendix 
A). The survey was launched August 29
th
, 2014 and closed September 14th, 2014 and 
therefore was active for a total of 17 days.  The survey was closed as the number of 
participants taking the survey had stagnated at zero and the desired sample size had been 




The current study uses a randomized trial administered via an online 
questionnaire in which two experimental groups were presented with a hypothetical 
genetic testing vignette followed by a series of questions. Provider recommendations 
were incorporated into the questionnaires and tailored to the participant using survey 
logic based on an information preference that each participant indicated in one survey 
question. A flow chart of the study design is found in Figure 2. 
Experimental Groups 
There were two questionnaire versions. Both questionnaire versions contained the 
same hypothetical vignette but they differed by the associated method of presenting the 
genetic testing choice. The same scales and demographic questions were administered to 
both groups.   
Group 1 received survey version 1.  Participants in this group were presented with 
a tiered approach to genetic test presentation. All participants in group 1 were first 
offered a choice between two options- No Genetic Testing and a 5 Gene Test. After this 
decision, all participants who indicated that they would want the 5 Gene Test were asked 
to select an information preference.  This involved choosing whether they preferred (a) 
having only genetic information with clear meaning for their future health care, or (b) 
having all possible genetic information.  After answering this question, participants were 
presented with a third genetic test- a 15 Gene Test- and a recommendation for either the 5 
or 15 Gene Test based on their indicated information preference. They were then given 
the option to stay with or change their initial genetic test choice.  The information 
preference was elicited after the initial genetic testing choice because this enabled the 
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study of the impact of the number of options independently from the impact of a 
personalized recommendation.  Participants who had indicated that they did not want 
genetic testing when presented with the initial genetic testing choice were presented with 
an alternate question. They were told about the 15 Gene Test and asked if they would 
have wanted testing if they had been presented with this option. 
Participants in group 2 were presented with all three genetic testing options 
simultaneously - No Genetic Testing, the 5 Gene Test, and the 15 Gene Test. After 
making the initial genetic testing decision, all participants who indicated that they wanted 
either the 5 Gene Test or the 15 Gene Test were asked to indicate their information 
preference using the same question that was presented to group 1. They were then given a 
personalized recommendation for either the 5 Gene Test or 15 Gene Test based on their 
information preference and the option to stay with or change which testing option they 
selected. 
The 5 Gene Test and 15 Gene Test varied by the number of genes tested and the 
following factors: the likelihood of receiving a result that is uncertain, the likelihood of 
receiving a result with unclear implications for cancer risk, and a different time to test 
result. The value of each of these attributes increases with more genes tested. These 
trade-offs between each test would be equivalent to the tradeoffs experienced between 
undergoing a cancer-specific high penetrance gene panel and a cancer-specific gene panel 
with high and moderate penetrance genes. 
Survey Instrument 
The survey instrument was an online questionnaire which contained four sections; 
informed consent, hypothetical vignette/genetic testing information, genetic testing 
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preference questions, and scales/demographic questions. The survey was created and 
administered using Qualtrics Research Suite Software. Screen shots containing the survey 
content and appearance are found in Appendices B through F. 
Initial feedback on the survey was provided by members of the Johns 
Hopkins/NHGRI Genetic Counseling Training Program executive committee, and one 
practicing cancer genetic counselor.  Revisions were then made and the survey was pilot 
tested with a convenience sample of 5 community members with limited knowledge of 
genetics.  Changes were made based on their feedback.  Based on information from this 
pilot it was projected that the survey would take 10-15 minutes to complete. The final 
version of the survey was reviewed by two members of the author’s thesis committee 
prior to launch. 
Survey Flow 
Participants could not move on to the next question if the initial genetic testing 
decision was not answered.  All other questions were optional; however, participants 
received a pop up message informing them when they skipped questions with a choice to 
return and answer those questions or proceed to the next page.  Once a participant 
proceeded to the next page he/she could not return to the previous page.  Some questions 
had randomization of response options. 
Consent 
Clicking on the survey link directed participants to the first page of the survey 
instrument which was a consent statement outlining the purpose of the study, survey 
content, potential risks and benefits, confidentiality information, and the contact 
22 
 
information of the researchers.  In order to consent to participate in the study, participants 
needed to continue to the next page of the survey. 
Hypothetical Vignette 
A hypothetical vignette was generated based on the author’s clinical experience, 
data from the literature, and quantitative data about the design of hypothetical vignettes 
for genetic testing.  It contained four sections; the hypothetical situation, what could be 
learned from genetic testing, what would happen if a positive result was found, and the 
logistics of genetic testing.  The hypothetical situation involved the participant receiving 
a referral to genetic counseling based on a family history that involved early onset breast 
and prostate cancers in the participant’s mother, uncle, and grandfather.  The scenario 
was loosely based on the constellation of cancers seen in HBOC with an overemphasis on 
prostate cancer to enhance relevance to male participants.  In addition to their 
involvement in HBOC, breast and prostate cancers were chosen because these cancers are 
common and more likely to be familiar to members of the general population. 
Genetic Testing Decisions 
Participants were asked to make a series of genetic testing-related decisions as 
outlined in the study design section of the methods.  
Scales 
Four pre-existing scales were used to measure the concepts of decisional conflict, 
intolerance for uncertainty, genetic literacy, and subjective numeracy.  Additional 
questions were used to discern understanding of the scenario, anticipated decisional 
regret, and genetic comprehension. 
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Decisional Conflict was measured using a compilation of questions from the 
Decisional Conflict Scale by AM O’Connor (O’Connor, 1995), and a modified version of 
this scale tailored to HBOC genetic testing decisions (Katapodi, Munro, Pierce, & 
Williams, 2011).  Neither scale was used in its full form because not all questions made 
sense in the context of genetic testing and/or a hypothetical scenario.  This concept was 
measured in order to determine if using a tiered versus menu approach to genetic testing 
related to decisional conflict scores.  Decisional conflict was of interest because this is 
one type of decision making outcome that extends beyond the actual choice made.  
Anticipated decisional regret was assessed using one question appended to this scale and 
was added as an additional outcome of decision making and factor of descriptive interest. 
Intolerance for uncertainty was measured using the Short Form of the Intolerance 
for Uncertainty Scale (Carleton, Norton, & Asmundson, 2007).  This concept was 
measured because it is a person-related factor that could potentially explain some 
variation in outcomes since the genetic tests presented to participants varied in the 
probability of results with unclear clinical implications. 
Genetic familiarity was measured using a modified version of the Rapid Estimate 
of Adult Literacy in Genetics (REAL-G) for survey form (Erby & Roter, 2008). Genetic 
comprehension was also measured using questions created from the words on this scale.  
These scores were administered to determine estimates of the genetic literacy of the study 
participants and whether genetic literacy and comprehension related to variation in 
outcomes. 
Numeracy was measured using the Subjective Numeracy Scale (Zikmund-Fisher, 
Smith, Ubel, & Fagerlin, 2007).  This concept was measured to gain a sense of the overall 
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subjective numeracy level of the study participants because the genetic testing decision 
involved processing numerical and probabilistic information. 
 A question was added to assess self-reported understanding of the hypothetical 
vignette and genetic testing scenario. The purpose of this question was to aid assessment 
of the quality of the vignette based on whether participants felt that they were able to 
understand it. 
Demographics 
A series of questions were asked about the participants’ experiences with cancer 
including his/her number of relatives with cancer, perceived cancer risk, anxiety about 
developing cancer, cancer screening behaviors, and personal and/or family history of 
cancer genetic testing.  Participants were also asked to rate their overall health.  These 
factors were measured because it was hypothesized that a participants’ personal 
experiences with and perceptions of cancer may relate to their genetic testing choices and 
information preferences.  
Additional demographic information was collected including the participants’ sex, 
age, education, income, number of biological children, employment status, race, 
ethnicity, state of residence, political beliefs, relationship status, and whether his/her 
native language was English.  These were measured as additional person-related factors 
that could potentially relate to study outcomes and as factors of descriptive interest. 
Compensation 
Participants received a $10.00 amazon.com electronic gift card if they entered an 




Data Analyses were performed using Stata12 IC. The likelihood of undergoing 
genetic testing by survey group and the likelihood of a test choice matching information 
preferences were investigated using bivariate and multivariate logistic regressions. 
Covariates were included in the multivariate models if they reached statistical 
significance of p≤0.05 when a separate regression was run with each variable included as 
a single covariate.  Covariates significant for one genetic testing outcome (i.e. final 
testing option chosen) were included in the other multivariate analyses to facilitate cross 
comparisons of the results.  The variables sex and age were included in the multivariate 
analyses for theoretical reasons despite not reaching the inclusion cutoff.   
The final genetic test chosen by group was investigated using ordinal logistic 
regression.  The changes in genetic testing choices before and after a provider 
recommendation were examined using a Wilcoxon matched-pairs signed-rank test using 
only the data from Group 2. 
Variables 
Independent variables:  
1.) Group 1 or Group 2 membership which is equivalent to: 
a. # of options presented (2 or 3)  
b. Genetic test presentation method (Step-wise or side-by-side) 
2.) Genetic testing option chosen- initial choice for Group 2 only 
a. Answer to “Genetic Testing Choice 1” for Group 2 only (No Testing, 5-
Gene Test, 15-Gene Test) 
3.) Concordance between Information Preference and Initial Genetic Testing Option 
Selected, Group 2 Only 
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a. Match = Selecting: 
i. 5 Gene Test and (a) having only genetic information with clear 
meaning for their future health care 
ii.  or 15 Gene Test (b). having all possible genetic information 
b. Mismatch= Selecting the 5 Gene Test and (b) or the 15 Gene Test and (a). 
Dependent variables: 
1.) Decision to have genetic testing or not- initial choice  
a. Answer to “Genetic Testing Choice 1” made binary (No Testing, Yes 
Testing) 
2.) Decision to have genetic testing or not- initial choice accounting for answers of 
group 1 non-testers when asked if they would want the 15-gene test 
a. Answer to “Genetic Testing Choice 1” + testing preference for 15 gene 
test among Group 1 no-testers (No Testing, Yes Testing) 
3.) Genetic testing option chosen- final choice  
a. Genetic Test Choice from “Provider Recommendation” +  Non Testers 
from “Genetic Testing Choice” (No Testing, 5-Gene Test, 15-Gene Test) 
4.) Genetic testing option chosen- final choice , Group 2 only 
a. Genetic Test Choice from “Provider Recommendation” +  Non Testers 
from “Genetic Testing Choice” for Group 2 only (No Testing, 5-Gene 
Test, 15-Gene Test) 
5.) Concordance between Information Preference and Final Genetic Testing Option 
Selected, Group 2 Only 
a. Match = Selecting: 
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i. 5 Gene Test and (a) having only genetic information with clear 
meaning for their future health care 
ii.  or 15 Gene Test and (b). having all possible genetic information 
b. Mismatch= Selecting the 5 Gene Test and (b) or the 15 Gene Test and (a) 
c. Other= Selecting “No Genetic Testing” 
6.) Concordance between Information Preference and Final Genetic Testing Option 
Selected 
a. See explanation under 5.) above for details 
7.) Decisional Conflict Scale Score 
a. Numerical score calculated from questions on decisional conflict scale 
Other demographic variables may be incorporated into multivariate models 
TABLES AND FIGURES 
Figure 1. Conceptual framework of factors affecting decision making 
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Figure 1. Flow chart of study design. White boxes indicate that the survey question 
content varied by group.  Survey logic was used to administer personalized follow-up 





  Group 1 - Number of People 
(%) 
Group 2 - Number of 
People (%) 
Age 18-44 360  (45.8) 360 (45.3) 
45-64 271 (34.5) 260 (32.7) 
65+ 152 (19.3) 170 (21.4) 
Unknown 3 (0.4) 4 (0.5) 
Total 786 794 
Sex  M 340 (43.3) 356 (44.8) 
F 436 (55.5) 423 (53.3) 
Unknown 10 (1.3) 15 (1.9) 
Total 786 794 
Race  White 348 (44.3) 389 (50.0) 
Black/AA 301 (38.3) 286 (36.0) 
Asian/Pacific 
Islander 
40 (5.1) 37 (4.7) 
Hispanic 49 (6.2) 39 (4.9) 
Native American 5 (0.6) 3 (0.4) 
Multiple Races 17 (2.2) 16 (2.0) 
Unknown 26 (3.3) 24 (3.0) 
Total 786 794 






 Group 1 




N,  (% of 
Initial 
Dataset) 
Initial Dataset 786, (100) 794, (100) 
Email Distribution List after Loading 
into Qualtrics 
780, (99.2) 790, (99.5) 
Emails Bounced 102, (13.0) 89, (11.2) 
Opened Email 425, (54.1) 425, (53.5) 
Clicked on Survey Link 263, (33.5) 250, (31.5) 
Consented to Study 248, (31.6) 237, (29.8) 
Completed Survey 215, (27.4) 204, (25.7) 
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PART 2: MANUSCRIPT 
ABSTRACT 
Objective: 
To examine how the presentation of a decision can influence choices about genetic 
testing for inherited cancer predispositions. Specifically, how the number of options and 
the addition of a personalized recommendation might influence outcomes such as the 
likelihood of undergoing genetic testing, the genetic test chosen, and whether a person’s 
test choice matches their personal preferences. 
Methods: 
An online hypothetical vignette study was completed by 454 healthy volunteers.  Each 
participant was randomized to receive one of two survey versions which differed in the 
manner of presenting testing options and how these options were integrated with a 
provider recommendation. Regression analyses were performed to determine the 
relationships between the presentation of choice and participant decisions. Wilcoxon 
rank-sign tests were used to determine the impact of a provider recommendation on final 
genetic testing choices.  
Results:  
Participants were more likely to choose to have genetic testing when presented with three 
options instead of two (OR: 2.00 p=0.014).  This effect was no longer observed when 
individuals who had decided not to undergo testing were presented with a third option 
(OR: 0.90 p=0.775).   The addition of a provider recommendation did not significantly 
change the overall distribution of options chosen (p=0.746). However, after a 
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recommendation, participants were more likely to choose the test that best matched with 
personal preferences about the type of genetic information desired (p<0.001). 
Conclusions: 
Participants were more likely to undergo genetic testing when presented with 3 options 
instead of 2.  They were also more likely to select an option in line with a personal 
preference if presented with a recommendation based on this preference. 
Practice Implications: 
The way providers’ structure preference-based medical choices for patients and the 
advice they give may influence which options are selected. 
1.0 INTRODUCTION 
Genetics is one area of medicine in which many new medical testing options have 
become available in a short period of time due to rapid technological advancements.  The 
abundance of clinical testing options has made decision making about genetic testing 
more complex for patients and providers.  Furthermore, the way providers choose to 
structure and present genetic testing choices may influence the ultimate decisions that 
clients make and their subsequent medical care.  The objective of the following 
hypothetical vignette study is to examine how the structure and presentation of genetic 
testing, specifically the number of testing options and a personalized recommendation 
from a health care provider, can influence the genetic test chosen in regard to hereditary 
cancer predispositions.  
1.1 Inherited Cancers 
Some individuals are born with a genetic mutation that places them at an 
increased lifetime risk to develop specific types of cancer, often at younger ages than 
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people in the general population.  These individuals are said to have a hereditary cancer 
syndrome, and it is believed that about 5-10% of all cancers are inherited via this 
mechanism (Garber & Offit, 2005). There are more than 45 identified syndromes with 
clear genetic causes that confer an increased lifetime risk of developing cancer (Riley et 
al., 2012).  These syndromes can differ on many dimensions including the types of 
cancer, the magnitude of the risks, the inheritance pattern, and whether individuals have 
other physical symptoms. 
One of the most common hereditary cancer syndromes is called Hereditary Breast 
and Ovarian Cancer Syndrome (HBOC). HBOC is caused by a deleterious mutation in 
either the BRCA1 or BRCA2 gene (Garber & Offit, 2005). This syndrome is associated 
with elevated lifetime risks of developing certain cancers including up to an 80% lifetime 
chance to develop female breast cancer, 40% chance to develop ovarian cancer, and 
elevated risks for prostate and pancreatic cancers (Petrucelli, Daly & Feldman, 2013).  
Approximately 1 in 800 women in the general population and 1 in 40 women of 
Ashkenazi Jewish ancestry have this condition (Schneider, 2012). 
1.2 Genetic Testing for Inherited Cancers 
Genetic testing can be used to identify individuals with hereditary cancer 
syndromes and inform their cancer risk assessments. Typically, a person would come to 
clinical attention as a candidate for hereditary cancer testing based on a notable family or 
personal history of cancer or if a mutation is identified in a relative. Individuals identified 
as having elevated risks for cancer by genetic testing may use these results to guide 
medical management decisions about cancer treatment, screening and/or prevention with 
the objective of reducing cancer morbidity and mortality. For example, women identified 
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as having HBOC may decide to have increased breast surveillance or have prophylactic 
surgeries such as a bilateral mastectomy or salpingo-oophorectomy due to their high risk 
of breast and ovarian cancers. Genetic test results can also be useful for guiding genetic 
testing in relatives and informing their cancer risks.  
Although some information learned from genetic testing has clinical utility, 
genetic testing can also provide information with unclear implications for clinical care. 
For example, it is possible to learn about risks for cancers that cannot be screened for or 
prevented.   The interpretation of genetic testing results is also limited by incomplete 
supporting information.  Testing of genes that have not been rigorously studied and/or 
confer moderately increased risks for cancer can lead to a result that does not have clear 
implications for cancer risks, surveillance and/or prophylactic surgeries. Additionally, 
testing of any gene can return a result of uncertain clinical significance. This means that 
an individual has a genetic change that has not been observed before or is not sufficiently 
understood to be classified as disease causing or not.  Furthermore, a negative genetic test 
result does not indicate a decreased risk of cancer unless a family member has previously 
been found to have a deleterious mutation in the gene examined.  
Genetic testing for inherited cancers has become more complex over time as next-
generation sequencing technologies have enabled companies to offer various panel tests 
that contain multiple genes (Hall et al., 2014). At this time there are four general 
approaches to cancer genetic testing including the following: 
1.) Syndrome specific test (e.g. testing for HBOC) 
2.) Cancer-specific high penetrance gene panel (e.g. genes for several syndromes that 
cause a high-risk for breast cancer) 
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4.) Cancer-specific gene panel with high and moderate penetrance genes (e.g. many 
genes that have some association with increased breast cancer risk) 
5.) “Comprehensive” cancer panels that include genes associated with multiple 
cancers or hereditary cancer syndromes ( e.g. genes associated with HBOC, 
Lynch Syndrome and other cancer syndromes) (Hall et al., 2014). 
Each of these approaches has distinct clinically relevant advantages and 
disadvantages which constitute trade-offs in choosing one method over another.  
Generally, it is up to patients to decide if they would like to have genetic testing, and in 
cases with multiple medically appropriate tests, which test is the best fit for their 
preferences  (Riley et al., 2012).  This process can be challenging for both patients and 
providers. 
1.3 Decision Making 
Studies of decision making have found that people are not completely rational 
decision makers and their decisions deviate from rational choice in predictable ways 
across many scenarios (Mather et al., 1998).  This has relevance for how providers 
present information upon which a medical decision will be based (Thaler & Sunstein, 
2009).  In the case of genetic testing, the way health care providers choose to structure 
and present testing choices to clients may influence the choice made.  
Findings suggest that the number of options presented to people when making a 
decision, for instance when patients are forced to choose from multiple medically 
appropriate options, affects the decision made (Tversky & Kahneman, 1974). In the 
theory of rational choice, it is implied that a preference between options cannot be altered 
by the addition of new alternatives.  However, there is evidence to suggest that people’s 
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preference between two options may depend on the presence or absence of a third 
alternatives (Simonson, 1989).  This is thought to occur because the relative 
attractiveness of options changes the way people evaluate them. 
Another way in which providers can influence a patient’s medical decision is whether 
or not they provide a recommendation.  A population-based study by Bosompra et al., 
(2000) indicated that participants were more likely to have genetic testing with a provider 
recommendation.  Furthermore, a survey of 426 women considered at risk for breast 
cancer, reported that 82% of participants would want providers to make a 
recommendation about breast cancer susceptibility testing(Geller & Bernhardt, 1998).  
Patients may also differ in the type of recommendations they prefer.  For example, a 
qualitative study about breast cancer susceptibility testing found that among those who 
desired a provider recommendation, preferences varied between hearing a single 
recommended course of action or all of the options available before making a decision 
(Geller et al., 1997).   
 This study seeks to investigate whether the ways in which genetic testing choice 
is presented can influence which tests are chosen and the likelihood of undergoing 
genetic testing in the context of hypothetical hereditary cancer predisposition testing.  
Specifically, this study was designed to examine if the number of testing options offered 
and an accompanying provider recommendation for one of the test options would 
influence a hypothetical decision about genetic testing for hereditary cancer 
predisposition.   
2.0 METHODS 
2.1 Study Population and Randomization 
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A list of potential study participants was obtained from the healthy volunteers 
database at the National Institutes of Health.  This database contains individuals who are 
willing to be contacted about opportunities to participate as healthy volunteers in 
biomedical research studies through the NIH intramural research program. A subset of 
people from this list were selected for email invitation using random number generation 
with oversampling of older age groups (relative to a census representative distribution) to 
account for anticipated differences in internet usage patterns.  Potential participants were 
randomized to an experimental group (Group 1 or Group 2) using random number 
generation.  Exclusion criteria included being under 18 years of age and not having an 
email address in the database.  
2.2 Survey Distribution 
Potential participants received an email invitation to participate in the study with a 
personalized link to the online survey.  Each link enabled one-time completion of the 
survey and allowed the participant to return to a partially completed survey. The survey 
was active for a total of 17 days in August and September 2014. The survey was closed 
because the number of participants taking the survey had stagnated at zero over time and 
the desired sample size had been achieved.  Participants had the option to receive a 
$10.00 gift card incentive for survey completion. 
2.3 Study Design and Survey Instrument 
This quantitative study was a randomized trial with two experimental groups.   
Each group was presented with a hypothetical genetic testing vignette followed by a 
series of genetic testing decisions, scales and measures, and demographic questions.  
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Groups differed by the questions that elicited genetic testing decisions, however, the 
hypothetical vignette and all other survey questions remained constant.   
The experimental portion of the survey had two components. The first component 
was designed to determine the impact of the number of options on the likelihood of 
undergoing genetic testing.  The second component was to investigate the impact of a 
personalized provider recommendation on genetic testing decisions.  A flow chart of the 
survey design is reflected in Figure 1. 
2.3.1 Hypothetical Vignette  
A hypothetical vignette was generated based on data about genetic testing for 
hereditary cancer predisposition in the literature, the author’s clinical experience, and 
quantitative data about the design of hypothetical vignettes for genetic testing (Figure 2).  
The scenario was loosely based on the constellation of cancers seen in HBOC with an 
overemphasis on prostate cancer to enhance relevance to male participants.  In addition to 
their involvement in HBOC, breast and prostate cancers were chosen because these 
cancers are common and more likely to be familiar to members of the general population.  
Before launch, the survey was reviewed by five individuals without a scientific 
background. 
2.3.2 Genetic Testing Options 
There were three possible genetic testing options that were designed to be 
equivalent to the choice between no testing, a cancer-specific high penetrance gene panel 
and a cancer-specific gene panel with high and moderate penetrance genes. These options 
are described in Table 1.  The genetic tests differed on three main categories correlated 
with the number and type of genes including the likelihood of receiving a result that is 
43 
 
uncertain, the likelihood of receiving a result that has unclear implications for cancer risk 
management, and a different time to test result. 
2.3.3 Number of Genetic Testing Options 
 The first genetic testing decision that participants made was designed to 
investigate the impact of the number of options presented (2 versus 3) on the likelihood 
of undergoing genetic testing.  Group 1 was presented with two genetic testing options; 
“No Genetic Testing” or a “5 Gene Test”. Group 2 was presented with a third option of a 
“15 Gene Test” in addition to the two options presented to Group 1.  Participants who 
chose  “No Genetic Testing” in group 1 were asked a follow-up question about whether 
they would have wanted genetic testing if they had been offered the “15 Gene Test”.    
2.3.4 Information Preference and Personalized Provider Recommendation 
 Following their initial genetic testing decision, all participants who chose to have 
a genetic test were asked to indicate an information preference for either (a) only genetic 
information with clear meaning for future health care or (b) having all possible genetic 
information.  Participants who indicated a preference for “only genetic information with a 
clear meaning for future health care” received a personalized recommendation for the “5 
Gene Test” and participants who preferred “having all possible genetic information” 
received a recommendation for the “15 Gene Test”.  Each participant who received a 
recommendation was given the option to remain with their initial choice or switch to 
another option.  Participants in group 1 who had opted for genetic testing were introduced 
to the “15 Gene Test” in conjunction with the personalized recommendation.  For 
participants in group 2, a personalized recommendation was the only intervention 
between their initial and final genetic testing choices. 
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2.3.5 Overall Method of Testing Presentation and Final Genetic Testing Choice 
The overall method of testing presentation reflects which survey version 
participants received and therefore how the options and a provider recommendation were 
presented to participants.  The impact of the overall method of testing presentation is 
illustrated by individuals’ final genetic testing choices.  The final genetic test choice each 
participant made was calculated using the final genetic test that each participant chose 
while taking the survey.   
Overall, group 1 participants received a tiered approach to genetic testing 
presentation and group 2 participants received a menu approach to genetic testing 
presentation. Group 1 participants were initially presented with two options, and then 
participants who had chosen the “5 Gene Test” were presented with a third option in 
conjunction with a provider recommendation and the opportunity to change their choice.  
Group 2 received a menu approach to genetic testing as they were initially offered all 
options and testers were later presented with provider recommendation and the option to 
change or remain with their initial choice. 
2.3.6 Measures and Demographics 
Decisional conflict was one decision making outcome of interest.  It was 
measured using a compilation of questions from the Decisional Conflict Scale by AM 
O’Connor (O’Connor, 1995), and a modified version of this scale tailored to HBOC 
genetic testing decisions (Katapodi et al., 2011).  Neither scale was used in its full form 
because only subsets of questions made sense in the context of genetic testing and/or a 
hypothetical scenario.   
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Three additional scales were used to measure the concepts of intolerance for 
uncertainty, genetic literacy, and subjective numeracy. Participants were also asked 
questions created by the authors to assess genetic comprehension, decisional regret, and 
self-reported understanding of the hypothetical vignette. These concepts were measured 
to be used for descriptive analyses and covariates. 
Intolerance for uncertainty was measured using the Short Form of the Intolerance 
for Uncertainty Scale (Carleton et al., 2007).  This concept was measured because it is a 
participant attribute that could have relevance to genetic testing decisions due to the 
inherent uncertainty associated with the outcomes of a decision and the probabilistic 
nature of genetic information. 
Genetic familiarity was measured using a version of the Rapid Estimate of Adult 
Literacy in Genetics (REAL-G) (Erby & Roter, 2008) modified for survey form. Genetic 
comprehension was also measured using questions created using the words from the 
REAL-G.  These scores were measured to determine estimates of the genetic literacy of 
the study participants. 
Numeracy was measured using the Subjective Numeracy Scale (Zikmund-Fisher 
et al., 2007).  This concept was measured to gain a sense of the overall subjective 
numeracy level of the study participants because the genetic testing decision involved 
processing numerical and probabilistic information. 
A question was added to assess self-reported understanding of the hypothetical 
vignette and genetic testing scenario. The purpose of this question was to aid the 
assessment of vignette quality based on whether participants felt that they were able to 
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understand it.  Anticipated decisional regret was assessed using an additional question in 
the same format as the decisional conflict scale. 
A series of further questions were asked about the participants’ actual experiences 
with cancer including his/her number of relatives with cancer, perceived cancer risk, 
anxiety about developing cancer, cancer screening behaviors, and personal and/or family 
history of cancer genetic testing.  Participants were also asked to rate their overall health. 
These factors were measured because it was hypothesized that a participants’ personal 
experiences with and perceptions of cancer may relate to their genetic testing choices and 
information preferences. 
Other demographic information was collected including the participants’ sex, age, 
education, income, number of biological children, employment status, race, ethnicity, 
state of residence, political beliefs, relationship status, and whether his/her native 
language was English. 
2.4 Data Analysis 
Data analyses were performed using Stata12 IC.  The likelihood of undergoing 
genetic testing by survey group and the likelihood of a test choice matching information 
preferences were investigated using bivariate and multivariate logistic regressions.  The 
final genetic test chosen by group was investigated using ordinal logistic regression.  
Covariates were included in the multivariate models if they reached statistical 
significance of p≤0.05 when a separate regression was run with each variable included as 
a single covariate.  Covariates significant for one genetic testing outcome (i.e. final 
testing option chosen) were included in the other multivariate analyses to facilitate cross 
comparisons of the results (Table 3).  The variables sex and age were included in the 
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multivariate analyses for theoretical reasons despite not reaching the inclusion cutoff. The 
changes in genetic testing choices before and after a provider recommendation were 
examined using a Wilcoxon matched-pairs signed-rank test using only the data from 
group 2. 
3.0 RESULTS 
3.1 Sample Description 
Of the 1580 emails sent to potential participants 485 (30.7%) individuals 
consented to the study and 419 (26.5%) completed the survey. The characteristics of 
participants are shown in Table 2.  93% (N=437) of individuals indicated they agreed or 
strongly agreed with the statement “I feel like I understood the medical scenario and 
genetic testing choice”. 
3.2 Impact of the Number of Genetic Testing Options 
79.4% of individuals in group 1 and 88.7% of individuals in group 2 chose to 
undergo genetic testing when first asked.  Among group 2 participants who decided to 
undergo testing, 38.0% chose the “5 Gene Test” and 50.7% chose the “15 Gene Test”.  
Overall, participants who were given three options (group 2) were significantly more 
likely to undergo genetic testing than participants who were given two options (group 1) 
(Table 3).  Participants who did not opt for testing in group 1 were then asked if they 
would have wanted genetic testing if presented with an additional option. 48.9% of these 
individuals said they would have wanted genetic testing if they had been told about the 
“15 Gene Test”.  If these individuals are counted as choosing to undergo genetic testing 
there is no longer a statistically significant difference in the likelihood of undergoing 
genetic testing by group (Table 3). 
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3.3 Impact a Personalized Provider Recommendation 
Responses of group 2 participants were used to determine the influence of a 
provider recommendation on genetic testing choice since this was the only factor 
manipulated between the initial and final testing decisions in this group.  The overall 
distribution of genetic testing options chosen was not significantly different after a 
provider recommendation compared to before (p=0.746).  However, test choice after a 
provider recommendation was significantly more likely to match the participant’s 
indicated information preference than before (p<0.001) (Table 4).  
3.4 Impact of the Overall Method of Testing Presentation 
There was no statistically significant difference between groups in the likelihood 
that the final testing option selected matched the participant’s information preference 
(Table 3).    Additionally, there was no significant difference in the overall distribution of 
genetic testing options selected by group.  However, members of group 2 were 
significantly more likely to choose genetic testing than members of group 1 (Table 3).  In 
group 1, 21.5% of individuals opted for “No Test”, 29.6% opted for the “5 Gene Test” 
and 48.9% opted for the “15 Gene Test”.  Among group 2 members, 11.8% opted for “No 
Test”, 36.2% opted for the “5 Gene Test” and 52.0% opted for the “15 Gene Test” 
(Figure 4). There was no significant difference in decisional conflict score by group 
(P=0.92). 
4.0 DISCUSSION AND CONCLUSION 
4.1 Discussion 
 Participants presented with 3 genetic testing options were more likely to choose 
genetic testing than participants offered only 2 testing options.   This effect was mitigated 
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by introducing the “15 Gene Test” to individuals who had opted against genetic testing 
and asking if they would have wanted testing if presented with this option.  It is unclear if 
this discrepancy is due to something uniquely attractive about the 10 additional genes on 
the “15 Gene Test” or if learning about an additional option changed the way people 
thought about the decision to have genetic testing or not by adding a point of comparison.  
These alternative interpretations could be addressed with future studies that add a “15 
Gene Test” vs “No Test” control or evaluate the relative attractiveness the attributes that 
varied between the testing options. 
The majority of individuals initially chose a test that was the best match for their 
information preferences.  Specifically, among participants opting for genetic testing, most 
individuals desiring as much genetic information as possible chose the “15 Gene Test” 
and those preferring only genetic information with clear meaning for their clinical care 
chose the “5 Gene Test”.  However, a subset of individuals did not initially select a 
genetic test that matched their information preference. A follow-up of the initial testing 
decision with a personalized recommendation that advocated for a test selection that 
matched this preference increased the likelihood that there was a match between the final 
test chosen and the preferred type of information.  This type of recommendation had the 
largest impact on the subset of individuals who initially selected a test that was not in line 
with their information preference, but not all individuals with a mismatched test and 
information preference changed their testing choice in response to the recommendation. 
Among those individuals who changed their choice in response to the 
recommendation, it is possible that the recommendation encouraged them to think more 
about what they wanted to learn from testing and what they would do with the genetic 
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information. It is also possible that some individuals did not initially have a strong 
preference for one test over another and the recommendation tipped the balance in favor 
of one test causing them to change their selection. Forcing participants to reconsider their 
initial choice could also lead to people second guessing their decisions and changing their 
choices.  
Individuals with a discordant information preference and final test choice may 
have considered another attribute of genetic testing more important than the information 
obtained from testing. For example, a person may want as much information as possible 
but strongly desire a test that has a faster turnaround time.  In this case, one may decide 
that the anxiety of waiting several additional weeks for a result is worse than not getting 
the information from a few additional genes. 
Although more individuals overall opted for the “15 Gene Test”, a sizable number 
still chose the “5 Gene Test”.  This indicates that adding additional genes to a test does 
not ensure that that test will be more desirable and there may be a reason to continue to 
offer smaller panels of well-studied genes.  Additionally, there was no evidence to 
indicate that offering an additional option which increases the complexity of the decision 
significantly influences decisional conflict. 
4.2 Conclusion 
 This study indicates that offering a third genetic testing option to all individuals 
may increase the likelihood that an individual will undergo genetic testing.  
Consequently, individuals who receive a tiered approach to testing and do not initially opt 
for the “5 Gene Test” would not have exposure to the “15 Gene Test” which decreases 
the overall likelihood of undergoing genetic testing with this approach.   
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This study also provides evidence that a personalized recommendation targeting 
information preferences may influence the testing choices of those individuals with a 
discrepancy between what type of information they prefer to learn and their testing 
choice.  Finally, the overall method of offering testing, a tiered versus a menu approach, 
did not significantly impact whether a person selected the “5 Gene Test” or the “15 Gene 
Test”.  It also did not significantly influence decisional conflict ratings.  
4.3 Limitations 
This study has several limitations.  One limitation is that the hypothetical nature of 
the vignette and genetic testing decisions differ from real-life genetic testing contexts.  
The patient-provider relationship and the social accountability that could stem from 
interpersonal communication are lost online.  Additionally, study participants likely did 
not have the same affective states of patients in a real-life setting who would be 
discussing difficult topics such as their family and personal histories of cancer and risks 
for future cancers.  Participants in the study would also not have been anticipating the 
receipt of actual genetic test results.  Additionally, the findings from this may not apply if 
a decision like this is presented in a very different way, for example, if every syndrome 
and/or gene contained on a panel test is discussed in detail with patients.  
Furthermore, although this study represented people of different ages and races, the 
individuals in the NIH healthy volunteers database are likely different than other general 
population samples and are concentrated in the Washington District of Columbia 
Metropolitan Area. 
4.4 Practice Implication 
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The way that providers present genetic testing choices to clients may influence the 
choices made.  It may be appropriate to present multiple testing options as people have 
different preferences for the types of information they value.  This is particularly relevant 
in settings with multiple medically appropriate tests with distinct trade-offs.  Encouraging 
patients to talk through how they value these trade-offs and the different downstream 
implications of potential test results is one approach that can be used to help facilitate 
informed decision making and give providers the information needed to make 
personalized recommendations. This study indicates that personalized recommendations 
using a similar approach may help people who have selected options that are not in line 
with their preferences.  Although this study did not collect information to elucidate the 




Figure 1. Flow chart of study design. White boxes indicate that the survey question 
content varied by group.  Survey logic was used to administer personalized follow-up 




This survey is based on a choice that is possible but not actually available to anyone. 
This survey should not be used as a source of medical fact.  You cannot return to 





 Please imagine that you have visited your family doctor to talk about your chance of 
having or developing cancer. You have told him that your mother, uncle and grandfather 
all had cancer, either breast or prostate cancer, when they were around 40 years of age. 
Your doctor is concerned about your family history and suggests that you see a genetic 
counselor to learn about genetic testing. The purpose of genetic testing is to see if you 
have a faulty gene that puts you at high risk for certain types of cancer.   
When you visit the genetic counselor she asks you questions about your family's cancer 
history.  Based on this, she says that you qualify for genetic testing.  She says that not 
everyone wants genetic testing because the results can be upsetting. It is up to you to 
decide if you want genetic testing or not.  In the next question you will be asked to make 
a (hypothetical) decision about undergoing genetic testing. Below is some information 
about genetic testing to help you with your decision. 
 
 
What You Could Learn from Genetic Testing 
 
You can get three types of results: 
 
Type of Result Explanation Meaning for your Cancer Risk 
Positive 
Result 
You have a faulty 
gene 
You are at higher risk get certain cancers in your 
lifetime than people without a faulty gene. For the 
faulty gene with the biggest cancer risk, about 8 in 
10 people will get cancer. Some cancers you could 
learn you are at risk for are breast, prostate, 
pancreatic and ovarian cancers. 
Negative 
Result 
No faulty gene was 
found 
You may not have inherited a faulty gene that gives 
you a high risk to have certain cancers. However, 
your family history may still put you at higher risk 
than the general public to get certain cancers. 




You have a change in 
a gene but it 
is unclear if this 
increases your risk of 
cancer. 
An unclear result means that the test cannot help 
determine your cancer risk at this time. 
Your family history may still put you at higher risk 
than the general public to get certain cancers. 






What Would Happen if You Have a Positive Result 
 
If you have a positive result (faulty gene found): 
 You will be told about your chance to develop certain cancers. 
 Doctors may recommend that you have certain tests to look for cancer (such as a 
mammogram or PSA testing), or surgeries to prevent cancer. 
 There may not be ways to find early and prevent every cancer you could be at 
high risk for. 
 Each of your children would have a 50% chance of having the same faulty gene. 





 Genetic testing is done on a tube of your blood. 
 There is 100 dollar copay for any type of genetic testing. 
 






5 Gene Test 15 Gene Test 
 
Description 
Looks at the 5 best-
studied genes that can 
cause breast and 
prostate cancers 
 
Looks at the 5 best-studied 
genes that can cause breast 
and prostate cancers and 10 
other genes that have been 





if a positive test 
Clear guidelines telling 




Clear guidelines telling your 
cancer risks and suggestions 
for screening for 5 
genes.  Meaning of a positive 
result for the 10 other genes is 
not well-established.  
Chance of an 
inconclusive 
result 
2 in 100 people have 
an inconclusive result 
15 in 100 people have an 
inconclusive result 
Time it takes to 
get your results 
3 weeks 8 weeks 







Age - % (N=211, 201)   
- 18-44 46.0 44.3 
- 45-64 33.6 29.9 
- 65+ 20.4 25.9 
Sex -% Female (N=214, 204) 58.9 59.8 
Race -% (N=212, 203)   
- White 59.0 70.0 
- Black or African American 30.2 20.7 
- Other 11 9.5 
Ethnicity -% Hispanic (N=214, 204) 5.1 3.4 
≥1 year of college - % (N=214, 204) 92.1 94.1 
Employment - % (N=213, 204)   
- Part-time or full-time 65.7 66.2 
- Retired 15.5 19.1 
- Unemployed or disabled 14.1 10.8 
- Job free by choice 4.7 3.9 
Native English Speaker -% (N=214, 204) 86.9 89.7 
Relationship Status- %(N=214, 202)   
- Married/Domestic Partnership 44.4 39.1 
- Divorced/Separated/Widowed 15.4 19.8 
- Single 40.2 41.1 
Biological Children -% with (N=213, 204) 50.7 46.1 
Subjective Numeracy Score –mean (N=215, 207) 4.76 4.80 
% Correct Genetic Comprehension Questions- mean (N=215, 207) 92.2 92.5 
Genetic Familiarity- mean score (N=217, 208) 5.9 5.8 
Personal History of Cancer- % yes (N=215, 206) 7.9 7.8 
One or More First Degree Relatives with Cancer History - % yes 
(N=215, 206) 
45.1 45.1 
Personal History of any Cancer Screening- % yes (N=214, 206) 81.3 85.0 
Personal or Family History of Cancer Genetic Testing - % yes 
(N=214, 206) 
10.3 9.7 
Perceived Cancer Risk Relative to People of Same Age and 
Gender -% (N=214, 206) 
  
- Higher 10.7 11.2 
- Lower 52.3 52.9 
- Same 36.9 35.9 
Level of Anxiety about Developing Cancer- % (N=214, 206)   
- High 1.9 4.9 
- Moderate 23.4 27.7 
- Low 74.8 67.5 
Perceived Health- % Good or Excellent (N=214, 206) 93.5 94.7 




Table 3. Genetic testing decision outcomes by survey group membership. 
 
  Final Test Choice and Information Preference  





Match 134 9 1 144 
Do not Match 28 24 0 52 
Total 162 33 1 196 
Table 4. Concordance between participant information preference and genetic testing 
choices before and after a provider recommendation for group 2 participants. 






Initial likelihood of undergoing genetic 
testing (2 vs 3 options) 
2.03 0.008* 2.00 0.014* 
Initial likelihood of undergoing genetic 
testing (2 vs 3 options) accounting for 
Group 1 non-testers who would want the 
“15 Gene Test” 
0.94 0.843 0.90 0.755 
Final likelihood of undergoing genetic 
testing (tiered vs menu approach) 
2.05 0.006* 2.02 0.012* 
Final option chosen 1.31 0.135 1.30 0.160 
Final option concordance with information 
preference 
0.63 0.069* 0.62 0.080* 
*statistically significant (p≤0.05) 
+multivariate model controlling for sex, age, race, education, income, employment status, 
native English speaking, cancer screening behavior, perceived personal cancer risk, 
genetic comprehension, subjective numeracy, genetic familiarity, intolerance for 




Figure 4.  Genetic testing options selected.  a. The percentage of each option selected 
during the initial genetic testing choice by the number of testing options presented.  b. 
The percentage of each genetic testing option selected for the final genetic testing choice 
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APPENDIX A: Invitation Email 
Hello, 
My name is Marci and I am a researcher at the National Institutes of Health in the 
National Human Genome Research Institute. I received your name from the healthy 
volunteers program at the NIH and I would like to invite you to participate in study 
Decisions about Genetic Testing for Hereditary Cancer Predisposition. To participate in 
this study you would need to take a one-time survey.  The survey should take 15-25 
minutes to complete and you will receive a $10.00 electronic gift card to Amazon.com if 
you provide your email at the end of the survey. 
























































































APPENDIX D: Gift Card Distribution Message 
Hello, 
  
Thank you for participating in my study, Decisions about Genetic Testing for Hereditary 
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